Immunocore Holdings plc Financing Cash Flow
Immunocore Holdings plc (IMCR) reported Financing Cash Flow of $17.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Immunocore Holdings plc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $16.48M, a 349.18% increase year-over-year.
- Immunocore Holdings plc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $656.00K, a 74.28% decline year-over-year.
- Immunocore Holdings plc net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.28M.
- Immunocore Holdings plc net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.87M, a 842.42% increase year-over-year.
- Immunocore Holdings plc net cash provided by (used in) financing activities for fiscal 2025 was $12.37M, a 96.40% decline from fiscal 2024.
- Immunocore Holdings plc net cash provided by (used in) financing activities for fiscal 2024 was $343.88M, a 901.23% increase from fiscal 2023.
- Immunocore Holdings plc net cash provided by (used in) financing activities for fiscal 2023 was $34.35M, a 76.39% decline from fiscal 2022.
- Immunocore Holdings plc net cash provided by (used in) financing activities for fiscal 2022 was $145.44M, a 49.53% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $17.14M 10-Q · filed 2026-08-06 | $21.43M derived: sum of 3 quarters · filed 2026-08-06 | $23.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $656.00K 10-Q · filed 2026-05-06 | $4.94M derived: sum of 2 quarters · filed 2026-05-06 | $6.81M derived: sum of 3 quarters · filed 2026-05-06 | $10.48M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.15M derived: sum of 2 quarters · filed 2026-02-25 | $9.82M derived: sum of 3 quarters · filed 2026-08-06 | $12.37M 10-K · filed 2026-02-25 |
| 2025-09-30 | $1.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $5.54M derived: sum of 2 quarters · filed 2026-08-06 | $8.09M 10-Q · filed 2025-11-06 | -$43.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $6.22M 10-Q · filed 2026-08-06 | -$45.29M derived: sum of 3 quarters · filed 2026-08-06 | -$45.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.55M 10-Q · filed 2026-05-06 | -$48.96M derived: sum of 2 quarters · filed 2026-05-06 | -$48.76M derived: sum of 3 quarters · filed 2026-05-06 | -$49.58M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$51.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$51.31M derived: sum of 2 quarters · filed 2026-02-25 | -$52.13M derived: sum of 3 quarters · filed 2026-02-25 | $343.88M 10-K · filed 2026-02-25 |
| 2024-09-30 | $198.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$620.00K derived: sum of 2 quarters · filed 2025-11-06 | $395.39M 10-Q · filed 2025-11-06 | $401.65M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | -$818.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $395.19M 10-Q · filed 2025-08-07 | $401.45M derived: sum of 3 quarters · filed 2026-02-25 | $411.82M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $396.01M 10-Q · filed 2025-05-07 | $402.27M derived: sum of 2 quarters · filed 2026-02-25 | $412.64M derived: sum of 3 quarters · filed 2026-02-25 | $424.22M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $6.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $16.63M derived: sum of 2 quarters · filed 2026-02-25 | $28.21M derived: sum of 3 quarters · filed 2026-02-25 | $34.35M 10-K · filed 2026-02-25 |
| 2023-09-30 | $10.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $21.95M derived: sum of 2 quarters · filed 2024-11-06 | $28.09M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $11.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $17.72M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $6.14M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $145.44M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $288.19M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |